Hims & Hers Health (NYSE:HIMS - Free Report) had its price objective lifted by Bank of America from $18.00 to $21.00 in a research report sent to investors on Thursday morning,Benzinga reports. Bank of America currently has an underperform rating on the stock.
Several other analysts have also issued reports on the stock. Deutsche Bank Aktiengesellschaft lifted their target price on shares of Hims & Hers Health from $23.00 to $27.00 and gave the company a "hold" rating in a research report on Wednesday, November 6th. Morgan Stanley cut shares of Hims & Hers Health from an "overweight" rating to an "equal weight" rating and upped their price objective for the company from $42.00 to $60.00 in a research note on Tuesday. Citigroup cut shares of Hims & Hers Health from a "neutral" rating to a "sell" rating and upped their price objective for the company from $24.00 to $25.00 in a research note on Friday, January 10th. Piper Sandler upped their price objective on shares of Hims & Hers Health from $21.00 to $24.00 and gave the company a "neutral" rating in a research note on Monday, January 6th. Finally, TD Cowen reaffirmed a "buy" rating and set a $28.00 price objective on shares of Hims & Hers Health in a research note on Wednesday, November 20th. Two analysts have rated the stock with a sell rating, eight have given a hold rating and seven have assigned a buy rating to the company. According to MarketBeat, Hims & Hers Health presently has a consensus rating of "Hold" and a consensus price target of $28.53.
Check Out Our Latest Report on Hims & Hers Health
Hims & Hers Health Stock Down 26.1 %
Shares of NYSE HIMS traded down $17.32 during trading on Thursday, hitting $49.10. The company had a trading volume of 87,881,723 shares, compared to its average volume of 17,758,602. The stock has a fifty day simple moving average of $34.66 and a two-hundred day simple moving average of $25.48. Hims & Hers Health has a fifty-two week low of $9.25 and a fifty-two week high of $72.98. The firm has a market capitalization of $10.73 billion, a price-to-earnings ratio of 111.58 and a beta of 1.35.
Insider Buying and Selling at Hims & Hers Health
In other news, CEO Andrew Dudum sold 33,513 shares of the company's stock in a transaction that occurred on Monday, December 2nd. The shares were sold at an average price of $33.38, for a total value of $1,118,663.94. Following the transaction, the chief executive officer now directly owns 33,502 shares in the company, valued at approximately $1,118,296.76. This represents a 50.01 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, insider Soleil Boughton sold 4,152 shares of the company's stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $60.69, for a total transaction of $251,984.88. Following the completion of the transaction, the insider now owns 157,345 shares in the company, valued at approximately $9,549,268.05. This represents a 2.57 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 1,184,611 shares of company stock worth $40,338,442 in the last ninety days. 17.71% of the stock is owned by insiders.
Hedge Funds Weigh In On Hims & Hers Health
Several large investors have recently made changes to their positions in HIMS. Farallon Capital Management LLC lifted its holdings in shares of Hims & Hers Health by 64,338.5% in the 4th quarter. Farallon Capital Management LLC now owns 8,377,000 shares of the company's stock worth $202,556,000 after acquiring an additional 8,364,000 shares during the last quarter. Arrowstreet Capital Limited Partnership lifted its holdings in shares of Hims & Hers Health by 192.0% in the 4th quarter. Arrowstreet Capital Limited Partnership now owns 6,304,202 shares of the company's stock worth $152,436,000 after acquiring an additional 4,145,305 shares during the last quarter. Vanguard Group Inc. lifted its holdings in shares of Hims & Hers Health by 11.1% in the 4th quarter. Vanguard Group Inc. now owns 20,257,116 shares of the company's stock worth $489,817,000 after acquiring an additional 2,020,722 shares during the last quarter. Yong Rong HK Asset Management Ltd acquired a new position in shares of Hims & Hers Health in the 4th quarter worth approximately $41,104,000. Finally, Renaissance Technologies LLC lifted its holdings in Hims & Hers Health by 29.0% during the 4th quarter. Renaissance Technologies LLC now owns 6,951,152 shares of the company's stock worth $168,079,000 after buying an additional 1,562,302 shares in the last quarter. 63.52% of the stock is currently owned by institutional investors and hedge funds.
Hims & Hers Health Company Profile
(
Get Free Report)
Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.
See Also
Before you consider Hims & Hers Health, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Hims & Hers Health wasn't on the list.
While Hims & Hers Health currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
